Summary
5.54 -0.04(-0.72%)11/06/2024
Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp (ADPT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.72 | 18.64 | 3.05 | 29.38 | 72.98 | 16.04 | -80.11 | -86.18 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 5.54 | |
| Open | 5.64 | |
| High | 5.78 | |
| Low | 5.50 | |
| Volume | 277,847 | |
| Change | -0.04 | |
| Change % | -0.72 | |
| Avg Volume (20 Days) | 739,003 | |
| Volume/Avg Volume (20 Days) Ratio | 0.38 | |
| 52 Week Range | 2.28 - 5.80 | |
| Price vs 52 Week High | -4.48% | |
| Price vs 52 Week Low | 142.98% | |
| Range | 7.74 | |
| Gap Up/Down | -0.36 | |
Fundamentals | ||
| Market Capitalization (Mln) | 723 | |
| EBIDTA | -52,744,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 56.00 | |
| Book Value | 4.6200 | |
| Earnings Per Share | -1.3670 | |
| EPS Estimate Current Quarter | -0.4200 | |
| EPS Estimate Next Quarter | -0.4500 | |
| EPS Estimate Current Year | -1.4900 | |
| EPS Estimate Next Year | -1.6300 | |
| Diluted EPS (TTM) | -1.3670 | |
| Revenues | ||
| Profit Marging | -1.2989 | |
| Operating Marging (TTM) | -1.3070 | |
| Return on asset (TTM) | -0.1147 | |
| Return on equity (TTM) | -0.2671 | |
| Revenue TTM | 146,599,008 | |
| Revenue per share TTM | 1.0520 | |
| Quarterly Revenue Growth (YOY) | 0.5010 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -40,220,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.7838 | |
| Revenue Enterprise Value | 23.6450 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 141,132,000 | |
| Shares Float | 93,777,876 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 1.30 | |
| Institutions (%) | 83.02 | |
10/09 16:05 EST - globenewswire.com
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
08/29 07:30 EST - globenewswire.com
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies
08/22 16:03 EST - globenewswire.com
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
SEATTLE, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY.
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
SEATTLE, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY.
08/01 22:25 EST - seekingalpha.com
Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Karina Calzadilla – Head-Investor Relations Chad Robins – Chief Executive Officer and Co-Founder Kyle Piskel – Chief Financial Officer Susan Bobulsky – Chief Commercial Officer-MRD Conference Call Participants Mark Massaro – BTIG David Westenberg – Piper Sandler Tejas Savant – Morgan Stanley Dan Brennan – TD Cowen Andrew Brackmann – William Blair Rachel Vatnsdal – JPMorgan Sung Ji Nam – Scotiabank Operator Good day and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter 2024 Earnings Call.
Adaptive Biotechnologies Corporation (ADPT) Q2 2024 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Karina Calzadilla – Head-Investor Relations Chad Robins – Chief Executive Officer and Co-Founder Kyle Piskel – Chief Financial Officer Susan Bobulsky – Chief Commercial Officer-MRD Conference Call Participants Mark Massaro – BTIG David Westenberg – Piper Sandler Tejas Savant – Morgan Stanley Dan Brennan – TD Cowen Andrew Brackmann – William Blair Rachel Vatnsdal – JPMorgan Sung Ji Nam – Scotiabank Operator Good day and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter 2024 Earnings Call.
08/01 20:00 EST - zacks.com
Adaptive Biotechnologies (ADPT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Adaptive Biotechnologies (ADPT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Adaptive Biotechnologies (ADPT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Adaptive Biotechnologies (ADPT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
08/01 19:20 EST - zacks.com
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.33 per share a year ago.
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.33 per share a year ago.
08/01 16:05 EST - globenewswire.com
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2024.
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2024.
07/21 06:00 EST - investorplace.com
3 Precision Medicine Stocks Tailoring Treatments
Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant.
3 Precision Medicine Stocks Tailoring Treatments
Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant.
07/11 16:05 EST - globenewswire.com
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
05/31 07:30 EST - globenewswire.com
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers
05/29 16:05 EST - globenewswire.com
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL.
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL.
05/23 06:00 EST - investorplace.com
Mighty Mites: 3 Small-Cap Stocks Packing a Powerful Punch
To be completely upfront, small-cap stocks to buy are risky. They're the equivalent of plus-money bets or plus odds.
Mighty Mites: 3 Small-Cap Stocks Packing a Powerful Punch
To be completely upfront, small-cap stocks to buy are risky. They're the equivalent of plus-money bets or plus odds.
05/22 11:15 EST - fool.com
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood bought shares of Shopify, Intellia, and Adaptive Biotechnologies on Tuesday. Shopify has surrendered 26% of its value over the past two weeks since posting disappointing guidance.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood bought shares of Shopify, Intellia, and Adaptive Biotechnologies on Tuesday. Shopify has surrendered 26% of its value over the past two weeks since posting disappointing guidance.
05/08 18:43 EST - fool.com
Why Adaptive Biotechnologies Topped the Market Today
On a relatively sleepy day for the market, the biotech enjoyed a decent little price pop on earnings. Its first quarter results topped analyst estimates on both the top and bottom lines.
Why Adaptive Biotechnologies Topped the Market Today
On a relatively sleepy day for the market, the biotech enjoyed a decent little price pop on earnings. Its first quarter results topped analyst estimates on both the top and bottom lines.
05/07 20:59 EST - seekingalpha.com
Adaptive Biotechnologies Corporation (ADPT) Q1 2024 Earnings Call Transcript
Adaptive Biotechnologies Corporation. (NASDAQ:ADPT ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Kyle Piskel - CFO Susan Bobulsky - Senior Vice President, Diagnostics, clonoSEQ Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandberg Tom Stevens - TD Cowen Operator Good day and thank you for standing by.
Adaptive Biotechnologies Corporation (ADPT) Q1 2024 Earnings Call Transcript
Adaptive Biotechnologies Corporation. (NASDAQ:ADPT ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Kyle Piskel - CFO Susan Bobulsky - Senior Vice President, Diagnostics, clonoSEQ Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandberg Tom Stevens - TD Cowen Operator Good day and thank you for standing by.
05/07 20:30 EST - zacks.com
Compared to Estimates, Adaptive Biotechnologies (ADPT) Q1 Earnings: A Look at Key Metrics
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Compared to Estimates, Adaptive Biotechnologies (ADPT) Q1 Earnings: A Look at Key Metrics
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
05/07 18:41 EST - zacks.com
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Misses Revenue Estimates
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.40 per share a year ago.
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Misses Revenue Estimates
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.40 per share a year ago.
05/07 16:05 EST - globenewswire.com
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2024.
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2024.
04/17 16:05 EST - globenewswire.com
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
04/02 16:05 EST - globenewswire.com
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
SEATTLE, April 02, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a business update, including the conclusion of its recent strategic review, preliminary revenue for the first quarter ended March 31, 2024, and transition of the chief financial officer role. Strategic Review Update After evaluating a number of potential opportunities as part of the strategic review, Adaptive's management team and board of directors concluded that the current best outcome to maximize shareholder value is to operate the MRD and Immune Medicine businesses internally within Adaptive while increasing their independence from one another by restructuring each business with dedicated resources and separate segment reporting.
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
SEATTLE, April 02, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a business update, including the conclusion of its recent strategic review, preliminary revenue for the first quarter ended March 31, 2024, and transition of the chief financial officer role. Strategic Review Update After evaluating a number of potential opportunities as part of the strategic review, Adaptive's management team and board of directors concluded that the current best outcome to maximize shareholder value is to operate the MRD and Immune Medicine businesses internally within Adaptive while increasing their independence from one another by restructuring each business with dedicated resources and separate segment reporting.